Search

Your search keyword '"Riverol M"' showing total 160 results
Start Over Author "Riverol M"
160 results on '"Riverol M"'

1. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

Author

Jessen, Frank, Kramberger, M. G., Angioni, D., Aarsland, D., Balasa, M., Bennys, K., Boada, M., Boban, M., Chincarini, A., Exalto, L., Felbecker, A., Fliessbach, K., Frisoni, G. B., Garza-Martínez, A. J., Grimmer, T., Hanseeuw, B., Hort, J., Ivanoiu, A., Klöppel, S., Krajcovicova, L., McGuinness, B., Mecocci, P., de Mendonca, A., Nous, A., Ousset, P.-J., Paquet, C., Perneczky, R., Peters, O., Tabuas-Pereira, M., Piazza, F., Plantone, D., Riverol, M., Ruiz, A., Sacco, G., Santana, I., Scarmeas, N., Solje, E., Stefanova, E., Sutovsky, S., van der Flier, W., Welsh, T., Wimo, A., Winblad, B., Frölich, L., and Engelborghs, S.

Published
2024
Full Text
View/download PDF

6. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

Author

Frederiksen, K, Nielsen, T, Appollonio, I, Andersen, B, Riverol, M, Boada, M, Ceccaldi, M, Dubois, B, Engelborghs, S, Frolich, L, Hausner, L, Gabelle, A, Gabryelewicz, T, Grimmer, T, Hanseeuw, B, Hort, J, Hugon, J, Jelic, V, Koivisto, A, Kramberger, M, Lebouvier, T, Lleo, A, de Mendonca, A, Nobili, F, Ousset, P, Perneczky, R, Olde Rikkert, M, Robinson, D, Rouaud, O, Sanchez, E, Santana, I, Scarmeas, N, Sheardova, K, Sloan, S, Spiru, L, Stefanova, E, Traykov, L, Yener, G, Waldemar, G, Frederiksen K. S., Nielsen T. R., Appollonio I., Andersen B. B., Riverol M., Boada M., Ceccaldi M., Dubois B., Engelborghs S., Frolich L., Hausner L., Gabelle A., Gabryelewicz T., Grimmer T., Hanseeuw B., Hort J., Hugon J., Jelic V., Koivisto A., Kramberger M. G., Lebouvier T., Lleo A., de Mendonca A., Nobili F., Ousset P. -J., Perneczky R., Olde Rikkert M., Robinson D., Rouaud O., Sanchez E., Santana I., Scarmeas N., Sheardova K., Sloan S., Spiru L., Stefanova E., Traykov L., Yener G., Waldemar G., Frederiksen, K, Nielsen, T, Appollonio, I, Andersen, B, Riverol, M, Boada, M, Ceccaldi, M, Dubois, B, Engelborghs, S, Frolich, L, Hausner, L, Gabelle, A, Gabryelewicz, T, Grimmer, T, Hanseeuw, B, Hort, J, Hugon, J, Jelic, V, Koivisto, A, Kramberger, M, Lebouvier, T, Lleo, A, de Mendonca, A, Nobili, F, Ousset, P, Perneczky, R, Olde Rikkert, M, Robinson, D, Rouaud, O, Sanchez, E, Santana, I, Scarmeas, N, Sheardova, K, Sloan, S, Spiru, L, Stefanova, E, Traykov, L, Yener, G, Waldemar, G, Frederiksen K. S., Nielsen T. R., Appollonio I., Andersen B. B., Riverol M., Boada M., Ceccaldi M., Dubois B., Engelborghs S., Frolich L., Hausner L., Gabelle A., Gabryelewicz T., Grimmer T., Hanseeuw B., Hort J., Hugon J., Jelic V., Koivisto A., Kramberger M. G., Lebouvier T., Lleo A., de Mendonca A., Nobili F., Ousset P. -J., Perneczky R., Olde Rikkert M., Robinson D., Rouaud O., Sanchez E., Santana I., Scarmeas N., Sheardova K., Sloan S., Spiru L., Stefanova E., Traykov L., Yener G., and Waldemar G.

Abstract

Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

Published
2021

9. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)

Author

Chincarini, A, Peira, E, Morbelli, S, Pardini, M, Bauckneht, M, Arbizu, J, Castelo-Branco, M, Busing, K, de Mendonca, A, Didic, M, Dottorini, M, Engelborghs, S, Ferrarese, C, Frisoni, G, Garibotto, V, Guedj, E, Hausner, L, Hugon, J, Verhaeghe, J, Mecocci, P, Musarra, M, Queneau, M, Riverol, M, Santana, I, Guerra, U, Nobili, F, Chincarini A., Peira E., Morbelli S., Pardini M., Bauckneht M., Arbizu J., Castelo-Branco M., Busing K. A., de Mendonca A., Didic M., Dottorini M., Engelborghs S., Ferrarese C., Frisoni G. B., Garibotto V., Guedj E., Hausner L., Hugon J., Verhaeghe J., Mecocci P., Musarra M., Queneau M., Riverol M., Santana I., Guerra U. P., Nobili F., Chincarini, A, Peira, E, Morbelli, S, Pardini, M, Bauckneht, M, Arbizu, J, Castelo-Branco, M, Busing, K, de Mendonca, A, Didic, M, Dottorini, M, Engelborghs, S, Ferrarese, C, Frisoni, G, Garibotto, V, Guedj, E, Hausner, L, Hugon, J, Verhaeghe, J, Mecocci, P, Musarra, M, Queneau, M, Riverol, M, Santana, I, Guerra, U, Nobili, F, Chincarini A., Peira E., Morbelli S., Pardini M., Bauckneht M., Arbizu J., Castelo-Branco M., Busing K. A., de Mendonca A., Didic M., Dottorini M., Engelborghs S., Ferrarese C., Frisoni G. B., Garibotto V., Guedj E., Hausner L., Hugon J., Verhaeghe J., Mecocci P., Musarra M., Queneau M., Riverol M., Santana I., Guerra U. P., and Nobili F.

Abstract

Background: amyloid-PET reading has been classically implemented as a binary assessment, although the clinical experience has shown that the number of borderline cases is non negligible not only in epidemiological studies of asymptomatic subjects but also in naturalistic groups of symptomatic patients attending memory clinics. In this work we develop a model to compare and integrate visual reading with two independent semi-quantification methods in order to obtain a tracer-independent multi-parametric evaluation. Methods: We retrospectively enrolled three cohorts of cognitively impaired patients submitted to 18 F-florbetaben (53 subjects), 18 F-flutemetamol (62 subjects), 18 F-florbetapir (60 subjects)PET/CT respectively, in 6 European centres belonging to the EADC. The 175 scans were visually classified as positive/negative following approved criteria and further classified with a 5-step grading as negative, mild negative, borderline, mild positive, positive by 5 independent readers, blind to clinical data. Scan quality was also visually assessed and recorded. Semi-quantification was based on two quantifiers: the standardized uptake value (SUVr)and the ELBA method. We used a sigmoid model to relate the grading with the quantifiers. We measured the readers accord and inconsistencies in the visual assessment as well as the relationship between discrepancies on the grading and semi-quantifications. Conclusion: It is possible to construct a map between different tracers and different quantification methods without resorting to ad-hoc acquired cases. We used a 5-level visual scale which, together with a mathematical model, delivered cut-offs and transition regions on tracers that are (largely)independent from the population. All fluorinated tracers appeared to have the same contrast and discrimination ability with respect to the negative-to-positive grading. We validated the integration of both visual reading and different quantifiers in a more robust framework thus bri

Published
2019

13. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

Author

Frederiksen, K.S. Nielsen, T.R. Appollonio, I. Andersen, B.B. Riverol, M. Boada, M. Ceccaldi, M. Dubois, B. Engelborghs, S. Frölich, L. Hausner, L. Gabelle, A. Gabryelewicz, T. Grimmer, T. Hanseeuw, B. Hort, J. Hugon, J. Jelic, V. Koivisto, A. Kramberger, M.G. Lebouvier, T. Lleó, A. de Mendonça, A. Nobili, F. Ousset, P.-J. Perneczky, R. Olde Rikkert, M. Robinson, D. Rouaud, O. Sánchez, E. Santana, I. Scarmeas, N. Sheardova, K. Sloan, S. Spiru, L. Stefanova, E. Traykov, L. Yener, G. Waldemar, G.

Abstract

Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning. © 2020 John Wiley & Sons Ltd.

Published
2021

14. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

Author

Frederiksen, K.S., Nielsen, T.R., Appollonio, I., Andersen, B.B., Riverol, M., Boada, M., Ceccaldi, M., Dubois, B., Engelborghs, S., Frölich, L., Hausner, L., Gabelle, A., Gabryelewicz, T., Grimmer, T., Hanseeuw, B., Hort, J., Hugon, J., Jelic, V., Koivisto, A., Kramberger, M.G., Lebouvier, T., Lleó, A., Mendonça, A. de, Nobili, F., Ousset, P.J., Perneczky, R., Olde Rikkert, M., Robinson, D., Rouaud, O., Sánchez, E., Santana, I., Scarmeas, N., Sheardova, K., Sloan, S., Spiru, L., Stefanova, E., Traykov, L., Yener, G., Waldemar, G., Frederiksen, K.S., Nielsen, T.R., Appollonio, I., Andersen, B.B., Riverol, M., Boada, M., Ceccaldi, M., Dubois, B., Engelborghs, S., Frölich, L., Hausner, L., Gabelle, A., Gabryelewicz, T., Grimmer, T., Hanseeuw, B., Hort, J., Hugon, J., Jelic, V., Koivisto, A., Kramberger, M.G., Lebouvier, T., Lleó, A., Mendonça, A. de, Nobili, F., Ousset, P.J., Perneczky, R., Olde Rikkert, M., Robinson, D., Rouaud, O., Sánchez, E., Santana, I., Scarmeas, N., Sheardova, K., Sloan, S., Spiru, L., Stefanova, E., Traykov, L., Yener, G., and Waldemar, G.

Abstract

Item does not contain fulltext, OBJECTIVES: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. METHODS: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. RESULTS: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. CONCLUSIONS: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

Published
2021

16. Forceps Minor Region Signal Abnormality 'Ears of the Lynx': An Early MRI Finding in Spastic Paraparesis with Thin Corpus Callosum and Mutations in the Spatacsin Gene (SPG11) on Chromosome 15

Author

Riverol, M., Samaranch, L., Pascual, B., Pastor, P., Irigoyen, J., Pastor, M.A., De Castro, P., and Masdeu, J.C.

Subjects
Magnetic resonance imaging -- Genetic aspects, Attack helicopters -- Genetic aspects, Genetic research -- Genetic aspects, Skin diseases -- Genetic aspects, Neurosciences -- Genetic aspects, Health
Abstract

To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1552-6569.2008.00327.x Byline: M. Riverol (1), L. Samaranch (1), B. Pascual (1), P. Pastor (1), J. Irigoyen (1), M.A. Pastor (1), P. de Castro (1), J.C. Masdeu (1) Keywords: Hereditary spastic paraparesis with thin corpus callosum; SPG11; spatacsin; magnetic resonance imaging (MRI); forceps minor of the corpus callosum Abstract: ABSTRACT BACKGROUND AND PURPOSE A thin corpus callosum on magnetic resonance imaging (MRI) characterizes a type of autosomal recessive disorder with progressive spastic paraparesis and cognitive impairment. Known as Hereditary Spastic Paraparesis with Thin Corpus Callosum (HSP-TCC), it has been associated with mutations of the SPG11 gene. No other specific MRI findings have been reported. METHODS We studied with MRI four patients from three families with HSP-TCC who had identified causal mutations in the SPG11 gene. RESULTS In all individuals studied the region of the forceps minor of the corpus callosum, corresponding to the genu fibers, appeared bright on T2-weighted and dark on T1-weighted images. On axial sections, the frontal horn region bore a remarkable resemblance to the ears of a lynx, with the areas of abnormal signal reminiscent of the tufts of hair crowning the tips of the ears of this animal. Less specific findings included a box-shape appearance of the calloso-caudate angle and diffusely increased signal in the hemispheric white matter. CONCLUSION Abnormal MRI signal in the region of the forceps minor of the corpus callosum is a characteristic early imaging finding of HSP-TCC with SPG11 mutations. Author Affiliation: (1)From the Department of Neurology and Neurosurgery (MR, PP, MAP, PC, JCM); Clinica Universitaria de Navarra, and the Neuroimaging (JI, BP); and Neurogenetics Laboratories (LS), Division of Neurosciences, Center for Applied Medical Research, University of Navarra, and the 'Centro de Investigacion Biomedica en Red (CIBER)' (PP, BP, JI, MAP, JCM), Pamplona, Spain. Article History: Acceptance: Received April 12, 2008, and in revised form August 13, 2008. Accepted for publication September 25, 2008. Article note: Correspondence: Address correspondence to Joseph C. Masdeu, MD, PhD, Department of Neurology and Neurosurgery, Pio XII 36, 31008 Pamplona (Navarra), Spain, E-mail: masdeu@unav.es

Published
2009

19. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)

Author

Chincarini, A., primary, Peira, E., additional, Morbelli, S., additional, Pardini, M., additional, Bauckneht, M., additional, Arbizu, J., additional, Castelo-Branco, M., additional, Büsing, K.A., additional, de Mendonça, A., additional, Didic, M., additional, Dottorini, M., additional, Engelborghs, S., additional, Ferrarese, C., additional, Frisoni, G.B., additional, Garibotto, V., additional, Guedj, E., additional, Hausner, L., additional, Hugon, J., additional, Verhaeghe, J., additional, Mecocci, P., additional, Musarra, M., additional, Queneau, M., additional, Riverol, M., additional, Santana, I., additional, Guerra, U.P., additional, and Nobili, F., additional

Published
2019
Full Text
View/download PDF

20. “Ears of the Lynx” MRI Sign Is Associated with SPG11 and SPG15 Hereditary Spastic Paraplegia

Author

Pascual, B., primary, de Bot, S.T., additional, Daniels, M.R., additional, França, M.C., additional, Toro, C., additional, Riverol, M., additional, Hedera, P., additional, Bassi, M.T., additional, Bresolin, N., additional, van de Warrenburg, B.P., additional, Kremer, B., additional, Nicolai, J., additional, Charles, P., additional, Xu, J., additional, Singh, S., additional, Patronas, N.J., additional, Fung, S.H., additional, Gregory, M.D., additional, and Masdeu, J.C., additional

Published
2019
Full Text
View/download PDF

21. Estrategias psicosociales para fortalecer el afrontamiento de la enfermedad de Parkinson: perspectiva de pacientes, familiares y profesionales sociosanitarios = Psychosocial strategies to strengthen the coping with Parkinson's disease: Perspectives from patients, family carers and healthcare professionals

Author

Navarta-Sánchez, M.V., Caparrós, N., Ursúa Sesma, M.E., Díaz de Cerio Ayesa, S., Riverol, M., and Portillo, M.C.

Subjects
Mixed-methods, Family carers, Cope, Chronic Care Model, Chronic illness, Focus groups
Abstract

Objective: To explore the main psychosocial aspects which have influence on the coping with the disease in patients with Parkinson's disease (PD) and their family carers. Design: An exploratory qualitative study which constitutes the second phase of a mixed-methods project. Setting: Multicenter study carried out in Navarre in 2014 in collaboration with Primary Care of Navarre Service of Health-Osasunbidea, Clínica Universidad de Navarra and Navarre Association of Parkinson's patients. Participants: A total of 21 participants: 9 people with PD, 7 family carers and 5 healthcare professionals. Method: Participants were selected through purposive sampling. Focus groups were conducted until a suitable saturation data was achieved. Transcriptions were analysed by 2 researchers through a content analysis. Results: Three aspects that affected how patients and family carers coped with PD were identified: features of the clinical practice; family environment, and disease's acceptance. Taking account of these findings, some strategies which could foster these aspects from primary healthcare are suggested in order to improve the adjustment to the disease in patients and family carers. Conclusions: The healthcare in people with PD should have an integral approach that tackle the symptoms control in patients and also deal with psychosocial aspects that influence on the coping with the disease, in patients and family carers. © 2016 Elsevier España, S.L.U.

Published
2017

23. A measurement of the tau hadronic branching ratios

Author

Abdallah, J., Abreu, P., Adam, W., Adzic, P., Albrecht, T., Alderweireld, T., Alemany Fernandez, R., Allmendinger, T., Allport, P. P., Amaldi, U., Amapane, N., Amato, S., Anashkin, E., Andreazza, A., Andringa, S., Anjos, N., Antilogus, P., Apel, W., Arnoud, Y., Ask, S., Asman, B., Augustin, J. E., Augustinus, A., Baillon, P., Ballestrero, A., Bambadeo, P., Barbier, R., Bardin, D., Barker, G. J., Baroncelli, A., Battaglia, M., Baubillier, M., Becks, K., Begalli, M., Behrmann, A., Ben Haim, E., Benekos, N., Benvenuti, A., Berat, C., Berggren, M., Berntzon, L., Bertrand, D., Besancono, M., Besson, N., Bloch, D., Blom, M., Bluj, M., Bonesini, M., Boonekampo, M., P. S. L., Borisov, G., Botner, O., Bouqueto, B., T. J. V., Boyko, I., Bracko, M., Brenner, R., Brodet, E., Bruckman, P., Brunet, J. M., Bugge, L., Buschmann, P., Calvi, M., Camporesi, T., Canale, V., Carena, F., Castro, N., Cavallo, F., Chapkin, M., Charpentier, P., Checchia, P., Chierici, R., Chliapnikov, P., Chudoba, J., Chung, S. U., Ciesliklg, K., Collins, P., Contri, R., Cosmeo, G., Cossutti, F., Costaso, M. J., Crenne, D., Cuevas, J., D'Hondt, J., Dalmau, J., Silva, T. d., Silva, W. D., Ricca, G. D., Angelis, A. D., Boer, W. D., Clercq, C. D., Lotto, B. D., Maria, N. D., Min, A. D., Paula, L. d., Ciaccio, L. D., Simone, A. D., Doroba, K., Drees, J., Dris, M., Eigen, G., Ekelof, T., Ellerts, M., Elsing, M., Espirito, M. C., Fanourakis, G., Fassouliotis, D., Feindt, M., Fernandez, J., Ferrer, A., Ferro, F., Flagmeyer, U., Foeth, H., Fokitis, E., Fulda Quenzer, F., Fuster, J., Gandelman, M., Garciao, C., Gavillet, P., Gazis, E., Gokieli, R., Golob, B., Gomez Ceballos, G., Goncalves, P., Graziani, E., Grosdidiero, G., Grzelak, K., Guy, J., Haag, C., Hallgren, A., Hamacher, K., Hamilton, K., Haug, S., Hauler, F., Hedberg, V., Hennecke, M., Herrb, H., Hoffman, J., Holmgren, S., Holt, P. J., Houlden, M. A., Hultqvist, K., Jackson, J. N., Jarlskog, G., Jarry, P., Jeans, D., Johansson, E. K., Johansson, P. D., Jonsson, P., Joramb, C., Jungermann, L., Kapusta, F., Katsanevas, S., Katsoufis, E., Kernel, G., Kersevan, B. P., Kerzel, U., Kiiskinen, A., King, B. T., Kjaer, N. J., Kluit, P., Kokkinias, P., Kourkoumelis, C., Kouznetsov, O., Krumstein, Z., Kucharczykl, M., Lamsal, J., Leder, G., Ledroit, F., Leinonen, L., Leitnero, R., Lemonne, J., Lepeltiero, V., Lesiakl, T., Liebig, W., Liko, D., Lipniacka, A., Lopes, J. H., Lopez, J. M., Loukas, D., Lutz, P., Lyons, L., Macnaughton, J., Malek, A., Maltezos, S., Mandl, F., Marco, J., Marco, R., Marechal, B., Margoni, M., Marin, J., Mariotti, C., Markou, A., Martinez Rivero, C., Masik, J., Mastroyiannopoulos, N., Matorras, F., Matteuzzi, C., Mazzucato, F., Mazzucato, M., Nulty, R. M., Meroni, C., Migliore, E., Mitaroff, W., Mjoernmark, U., Moa, T., Moch, M., Moenig, K., Monge, MARIA ROBERTA, Montenegro, J., Moraess, D., Moreno, S., Morettini, P., Mueller, U., Muenich, K., Mulders, M., Mundim, L., Murray, W., Murynl, B., Myatt, G., Myklebust, T., Nassiakou, M., Navarria, F., Nawrocki, K., Nicolaidou, R., Nikolenko, M., Oblakowska Mucha, A., Obraztsov, V., Olshevski, A., Onofre, A., Oraval, R., Osterberg, K., Ouraou, A., Oyangureno, A., Paganoni, M., Paiano, S., Palacios, J. P., Palka, H., Papadopoulou, T. D., Pape, L., Parkes, C., Parodi, Fabrizio, Parzefall, U., Passeri, A., Passon, O., Peralta, L., Perepelitsao, V., Perrotta, A., Petrolini, Alessandro, Piedra, J., Pieri, L., Pierre, F., Pimenta, M., Piotto, E., Podobnik, T., Poireau, V., Pol, M. E., Polok, G., Pozdniakov, V., Pukhaeva, N., Pullia, A., Rames, J., Read, A., Rebecchi, P., Rehn, J., Reid, D., Reinhardt, R., Renton, P., Richard, F., Ridky, J., Riverol, M., Rodriguez, D., Romero, A., Ronchese, P., Roudeauo, P., Rovelli, T., Ruhlmann Kleider, V., Ryabtchikov, D., Sadovsky, A., Salmi, L., Salt, J., Sander, C., Savoy Navarro, A., Schwickerath, U., Segar, A., Sekulin, R., Siebe, M., Sisakian, A., Smadja, G., Smirnova, O., Sokolov, A., Sopczak, A., Sosnowski, R., Spassov, T., Stanitzki, M., Stocchi, A., Strauss, J., Stugu, B., Szczekowski, M., Szeptycka, M., Szumlak, T., Tabarellis, T., Taffard, A. C., Tegenfeldt, F., Timmermans, J., Tkatchev, L., Tobin, M., Todorovova, S., Tome, B., Tonazzo, A., Tortosao, P., Travnicek, P., Treille, D., Tristram, G., Trochimczuk, M., Troncon, C., Turluer, M., Tyapkin, I. A., Tyapkin, P., Tzamarias, S., Uvarov, V., Valenti, G., Dam, P. V., Eldik, J. V., Lysebetten, A. V., Remortel, N. v., Vulpen, I. V., Vegni, G., Veloso, F., Venus, W., Verdier, P., Verzi, V., Vilanova'O, D., Vitale, L., Vrba, V., Wahlen, H., Washbrook, A. J., Weiser, C., Wicke, D., Wickens, J., Wilkinson, G., Winter, M., Witek, M., Yushchenko, O., Zalewska, A., Zalewski, P., Zavrtanik, D., Zhuravlov, V., Zimin, N. I., Zintchenko, A., Zupan, M., Collaboration, D., Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches Subatomiques (IReS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Cancéropôle du Grand Est-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), DELPHI, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Pierre et Marie Curie - Paris 6 (UPMC), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Abdallah, J, Abreu, P, Adam, W, Adzic, P, Albrecht, T, Alderweireld, T, Alemany Fernandez, R, Allmendinger, T, Allport, P, Amaldi, U, Amapane, N, Amato, S, Anashkin, E, Andreazza, A, Andringa, S, Anjos, N, Antilogus, P, Apel, W, Arnoud, Y, Ask, S, Asman, B, Augustin, J, Augustinus, A, Baillon, P, Ballestrero, A, Bambade, P, Barbier, R, Bardin, D, Barker, G, Baroncelli, A, Battaglia, M, Baubillier, M, Becks, K, Begalli, M, Behrmann, A, Ben Haim, E, Benekos, N, Benvenuti, A, Berat, C, Berggren, M, Berntzon, L, Bertrand, D, Besancon, M, Besson, N, Bloch, D, Blom, M, Bluj, M, Bonesini, M, Boonekamp, M, Booth, P, Borisov, G, Botner, O, Bouquet, B, Bowcock, T, Boyko, I, Bracko, M, Brenner, R, Brodet, E, Bruckman, P, Brunet, J, Bugge, L, Buschmann, P, Calvi, M, Camporesi, T, Canale, V, Carena, F, Castro, N, Cavallo, F, Chapkin, M, Charpentier, P, Checchia, P, Chierici, R, Chliapnikov, P, Chudoba, J, Chung, S, Cieslik, K, Collins, P, Contri, R, Cosme, G, Cossutti, F, Costa, M, Crennell, D, Cuevas, J, D'Hondt, J, Dalmau, J, da Silva, T, da Silva, W, della Ricca, G, de Angelis, A, de Boer, W, de Clercq, C, de Lotto, B, de Maria, N, de Min, A, de Paula, L, di Ciaccio, L, di Simone, A, Doroba, K, Drees, J, Dris, M, Eigen, G, Ekelof, T, Ellert, M, Elsing, M, Espirito Santo, M, Fanourakis, G, Fassouliotis, D, Feindt, M, Fernandez, J, Ferrer, A, Ferro, F, Flagmeyer, U, Foeth, H, Fokitis, E, Fulda Quenzer, F, Fuster, J, Gandelman, M, Garcia, C, Gavillet, P, Gazis, E, Gokieli, R, Golob, B, Gomez Ceballos, G, Goncalves, P, Graziani, E, Grosdidier, G, Grzelak, K, Guy, J, Haag, C, Hallgren, A, Hamacher, K, Hamilton, K, Haug, S, Hauler, F, Hedberg, V, Hennecke, M, Herr, H, Hoffman, J, Holmgren, S, Holt, P, Houlden, M, Hultqvist, K, Jackson, J, Jarlskog, G, Jarry, P, Jeans, D, Johansson, E, Johansson, P, Jonsson, P, Joram, C, Jungermann, L, Kapusta, F, Katsanevas, S, Katsoufis, E, Kernel, G, Kersevan, B, Kerzel, U, Kiiskinen, A, King, B, Kjaer, N, Kluit, P, Kokkinias, P, Kourkoumelis, C, Kouznetsov, O, Krumstein, Z, Kucharczyk, M, Lamsa, J, Leder, G, Ledroit, F, Leinonen, L, Leitner, R, Lemonne, J, Lepeltier, V, Lesiak, T, Liebig, W, Liko, D, Lipniacka, A, Lopes, J, Lopez, J, Loukas, D, Lutz, P, Lyons, L, Macnaughton, J, Malek, A, Maltezos, S, Mandl, F, Marco, J, Marco, R, Marechal, B, Margoni, M, Marin, J, Mariotti, C, Markou, A, Martinez Rivero, C, Masik, J, Mastroyiannopoulos, N, Matorras, F, Matteuzzi, C, Mazzucato, F, Mazzucato, M, Mc Nulty, R, Meroni, C, Migliore, E, Mitaroff, W, Mjoernmark, U, Moa, T, Moch, M, Moenig, K, Monge, R, Montenegro, J, Moraes, D, Moreno, S, Morettini, P, Mueller, U, Muenich, K, Mulders, M, Mundim, L, Murray, W, Muryn, B, Myatt, G, Myklebust, T, Nassiakou, M, Navarria, F, Nawrocki, K, Nicolaidou, R, Nikolenko, M, Oblakowska Mucha, A, Obraztsov, V, Olshevski, A, Onofre, A, Orava, R, Osterberg, K, Ouraou, A, Oyanguren, A, Paganoni, M, Paiano, S, Palacios, J, Palka, H, Papadopoulou, T, Pape, L, Parkes, C, Parodi, F, Parzefall, U, Passeri, A, Passon, O, Peralta, L, Perepelitsa, V, Perrotta, A, Petrolini, A, Piedra, J, Pieri, L, Pierre, F, Pimenta, M, Piotto, E, Podobnik, T, Poireau, V, Pol, M, Polok, G, Pozdniakov, V, Pukhaeva, N, Pullia, A, Rames, J, Read, A, Rebecchi, P, Rehn, J, Reid, D, Reinhardt, R, Renton, P, Richard, F, Ridky, J, Rivero, M, Rodriguez, D, Romero, A, Ronchese, P, Roudeau, P, Rovelli, T, Ruhlmann Kleider, V, Ryabtchikov, D, Sadovsky, A, Salmi, L, Salt, J, Sander, C, Savoy Navarro, A, Schwickerath, U, Segar, A, Sekulin, R, Siebel, M, Sisakian, A, Smadja, G, Smirnova, O, Sokolov, A, Sopczak, A, Sosnowski, R, Spassov, T, Stanitzki, M, Stocchi, A, Strauss, J, Stugu, B, Szczekowski, M, Szeptycka, M, Szumlak, T, TABARELLI DE FATIS, T, Taffard, A, Tegenfeldt, F, Timmermans, J, Tkatchev, L, Tobin, M, Todorovova, S, Tome, B, Tonazzo, A, Tortosa, P, Travnicek, P, Treille, D, Tristram, G, Trochimczuk, M, Troncon, C, Turluer, M, Tyapkin, I, Tyapkin, P, Tzamarias, S, Uvarov, V, Valenti, G, van Dam, P, van Eldik, J, van Lysebetten, A, van Remortel, N, van Vulpen, I, Vegni, G, Veloso, F, Venus, W, Verdier, P, Verzi, V, Vilanova, D, Vitale, L, Vrba, V, Wahlen, H, Washbrook, A, Weiser, C, Wicke, D, Wickens, J, Wilkinson, G, Winter, M, Witek, M, Yushchenko, O, Zalewska, A, Zalewski, P, Zavrtanik, D, Zhuravlov, V, Zimin, N, Zintchenko, A, Zupan, M, Student Lab and Education, (Astro)-Particles Physics, Faculty of Sciences, Cossutti, F., DELLA RICCA, Giuseppe, Vitale, Lorenzo, J. ABDALLAH, P. ABREU, W. ADAM, P. ADZIC, T. ALBRECHT, T. ALDERWEIRELD, R. ALEMANY-FERNANDEZ, T. ALLMENDINGER, P.P. ALLPORT, U. AMALDI, N. AMAPANE, S. AMATO, E. ANASHKIN, A. ANDREAZZA, S. ANDRINGA, N. ANJOS, P. ANTILOGUS, W.D. APEL, Y. ARNOUD, S. ASK, B. ASMAN, J.E. AUGUSTIN, A. AUGUSTINUS, P. BAILLON, A. BALLESTRERO, P. BAMBADE, R. BARBIER, D. BARDIN, G.J. BARKER, A. BARONCELLI, M. BATTAGLIA, M. BAUBILLIER, K.H. BECKS, M. BEGALLI, A. BEHRMANN, E. BEN-HAIM, N. BENEKOS, A. BENVENUTI, C. BERAT, M. BERGGREN, L. BERNTZON, D. BERTRAND, M. BESANCON, N. BESSON, D. BLOCH, M. BLOM, M. BLUJ, M. BONESINI, M. BOONEKAMP, P.S.L. BOOTH, G. BORISOV, O. BOTNER, B. BOUQUET, T.J.V. BOWCOCK, I. BOYKO, M. BRACKO, R. BRENNER, E. BRODET, P. BRUCKMAN, J.M. BRUNET, L. BUGGE, P. BUSCHMANN, M. CALVI, T. CAMPORESI, V. CANALE, F. CARENA, N. CASTRO, F. CAVALLO, M. CHAPKIN, P. CHARPENTIER, P. CHECCHIA, R. CHIERICI, P. SHLYAPNIKOV, J. CHUDOBA, S.U. CHUNG, K. CIESLIK, P. COLLINS, R. CONTRI, G. COSME, F. COSSUTTI, M.J. COSTA, D. CRENNELL, J. CUEVAS, J. D'HONDT, J. DALMAU, T. DA SILVA, W. DA SILVA, G. DELLA RICCA, A. DE ANGELIS, W. DE BOER, C. DE CLERCQ, B. DE LOTTO, N. DEMARIA, A. DE MIN, L. DE PAULA, L. DI CIACCIO, A. DI SIMONE, K. DOROBA, J. DREES, M. DRIS, G. EIGEN, T. EKELOF, M. ELLERT, M. ELSING, M.C. ESPIRITO SANTO, G. FANOURAKIS, D. FASSOULIOTIS, M. FEINDT, J. FERNANDEZ, A. FERRER, F. FERRO, U. FLAGMEYER, H. FOETH, E. FOKITIS, F. FULDA-QUENZER, J. FUSTER, M. GANDELMAN, C. GARCIA, P. GAVILLET, EVANGELOS GAZIS, R. GOKIELI, B. GOLOB, G. GOMEZ-CEBALLOS, P. GONCALVES, E. GRAZIANI, G. GROSDIDIER, K. GRZELAK, J. GUY, C. HAAG, A. HALLGREN, K. HAMACHER, K. HAMILTON, S. HAUG, F. HAULER, V. HEDBERG, M. HENNECKE, H. HERR, J. HOFFMAN, S.O. HOLMGREN, P.J. HOLT, M.A. HOULDEN, K. HULTQVIST, J.N. JACKSON, G. JARLSKOG, P. JARRY, D. JEANS, E.K. JOHANSSON, P.D. JOHANSSON, P. JONSSON, C. JORAM, L. JUNGERMANN, F. KAPUSTA, S. KATSANEVAS, E. KATSOUFIS, G. KERNEL, B.P. KERSEVAN, U. KERZEL, A. KIISKINEN, B.T. KING, N.J. KJAER, P. KLUIT, P. KOKKINIAS, C. KOURKOUMELIS, O. KUZNETSOV, Z. KRUMSHTEIN, M. KUCHARCZYK, J. LAMSA, G. LEDER, F. LEDROIT, L. LEINONEN, R. LEITNER, J. LEMONNE, V. LEPELTIER, T. LESIAK, W. LIEBIG, D. LIKO, A. LIPNIACKA, J.H. LOPES, J.M. LOPEZ, D. LOUKAS, P. LUTZ, L. LYONS, J. MACNAUGHTON, A. MALEK, S. MALTEZOS, F. MANDL, J. MARCO, R. MARCO, B. MARECHAL, M. MARGONI, J.C. MARIN, C. MARIOTTI, A. MARKOU, C. MARTINEZ-RIVERO, J. MASIK, N. MASTROYIANNOPOULOS, F. MATORRAS, C. MATTEUZZI, F. MAZZUCATO, M. MAZZUCATO, R. MCNULTY, C. MERONI, E. MIGLIORE, W. MITAROFF, U. MJORNMARK, T. MOA, M. MOCH, K. MONIG, R. MONGE, J. MONTENEGRO, D. MORAES, S. MORENO, P. MORETTINI, U. MULLER, K. MUNICH, M. MULDERS, L. MUNDIM, W. MURRAY, B. MURYN, G. MYATT, T. MYKLEBUST, M. NASSIAKOU, F. NAVARRIA, K. NAWROCKI, R. NICOLAIDOU, M. NIKOLENKO, A. OBLAKOWSKA-MUCHA, V. OBRAZTSOV, A. OLSHEVSKY, A. ONOFRE, R. ORAVA, K. OSTERBERG, A. OURAOU, A. OYANGUREN, M. PAGANONI, S. PAIANO, J.P. PALACIOS, H. PALKA, T.D. PAPADOPOULOU, L. PAPE, C. PARKES, F. PARODI, U. PARZEFALL, A. PASSERI, O. PASSON, L. PERALTA, V. PEREPELITSA, A. PERROTTA, A. PETROLINI, J. PIEDRA, L. PIERI, F. PIERRE, M. PIMENTA, E. PIOTTO, T. PODOBNIK, V. POIREAU, M.E. POL, G. POLOK, V. POZDNYAKOV, N. PUKHAEVA, A. PULLIA, J. RAMES, A. READ, P. REBECCHI, J. REHN, D. REID, R. REINHARDT, P. RENTON, F. RICHARD, J. RIDKY, M. RIVERO, D. RODRIGUEZ, A. ROMERO, P. RONCHESE, P. ROUDEAU, T. ROVELLI, V. RUHLMANN-KLEIDER, D. RYABCHIKOV, A. SADOVSKY, L. SALMI, J. SALT, C. SANDER, A. SAVOY-NAVARRO, U. SCHWICKERATH, A. SEGAR, R. SEKULIN, M. SIEBEL, A. SISAKIAN, G. SMADJA, O. SMIRNOVA, A. SOKOLOV, A. SOPCZAK, R. SOSNOWSKI, T. SPASSOV, M. STANITZKI, A. STOCCHI, J. STRAUSS, B. STUGU, M. SZCZEKOWSKI, M. SZEPTYCKA, T. SZUMLAK, T. TABARELLI, A.C. TAFFARD, F. TEGENFELDT, J. TIMMERMANS, L. TKACHEV, M. TOBIN, S. TODOROVA, B. TOME, A. TONAZZO, P. TORTOSA, P. TRAVNICEK, D. TREILLE, G. TRISTRAM, M. TROCHIMCZUK, C. TRONCON, M.L. TURLUER, I.A. TYAPKIN, P. TYAPKIN, S. TZAMARIAS, V. UVAROV, G. VALENTI, P. VAN DAM, J. VAN ELDIK, A. VAN LYSEBETTEN, N. VAN REMORTEL, I. VAN VULPEN, G. VEGNI, F. VELOSO, W. VENUS, P. VERDIER, V. VERZI, D. VILANOVA, L. VITALE, V. VRBA, H. WAHLEN, A.J. WASHBROOK, C. WEISER, D. WICKE, J. WICKENS, G. WILKINSON, M. WINTER, M. WITEK, O. YUSHCHENKO, A. ZALEWSKA, P. ZALEWSKI, D. ZAVRTANIK, V. ZHURAVLOV, N.I. ZIMIN, A. ZINCHENKO, and M. ZUPAN

Subjects
Hadronic decay, Particle physics, Physics and Astronomy (miscellaneous), ENERGIES, Hadron, FOS: Physical sciences, Branching (polymer chemistry), 01 natural sciences, DECAYS, High Energy Physics - Experiment, BHABHA SCATTERING, High Energy Physics - Experiment (hep-ex), MONTE-CARLO, 0103 physical sciences, RADIATIVE-CORRECTIONS, LEP, FRACTIONS, RESONANCE, LEPTONS, PROGRAM, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], 010306 general physics, Engineering (miscellaneous), TAU LEPTON, DELPHI, Physics, 010308 nuclear & particles physics, BRANCHING RATIOS, HADRONS, LARGE ELECTRON POSITRON COLLIDER, PARTICLE PHYSICS, Particle Physics - Experiment, Lepton
Abstract

The exclusive and semi-exclusive branching ratios of the tau lepton hadronic decay modes (h- v_t, h- pi0 v_t, h- pi0 pi0 v_t, h- \geq 2pi0 v_t, h- \geq 3pi0 v_t, 2h- h+ v_t, 2h- h+ pi0 v_t, 2h- h+ \geq 2pi0 v_t, 3h- 2h+ v_t and 3h- 2h+ \geq 1pi0 v_t) were measured with data from the DELPHI detector at LEP., Comment: 53 pages, 18 figures, Accepted by Eur. Phys. J. C

Published
2006

24. Enfermedad de Alzheimer de inicio precoz y de inicio tardío: ¿son la misma entidad?

Author

Tellechea, P., Pujol, N., Esteve-Belloch, P., Echeveste, B., García-Eulate, M.R., Arbizu, J., and Riverol, M.

Abstract

La enfermedad de Alzheimer de inicio precoz (EAIP), definida como la que se manifiesta antes de los 65 años de edad, muestra ciertas características diferentes de la enfermedad de Alzheimer de inicio tardío (EAIT). Nuestro objetivo fue analizar los trabajos más actuales que comparan la clínica, la neuropsicología, la patología, la genética y la neuroimagen de la EAIP y la EAIT, para determinar si nos enfrentamos a dos enfermedades distintas o a variantes de una misma entidad. Como resultado, hallamos consistencia en algunas características diferenciales entre los 2 cuadros clínicos. Fundamentalmente, la EAIP comienza con mayor frecuencia con una clínica atípica; la valoración cognitiva muestra mayor afectación de las funciones ejecutiva y visuoespacial y de las praxias, y menor afectación de la memoria; la neuropatología evidencia mayor densidad y una distribución más difusa de la patología tipo Alzheimer; los estudios de neuroimagen estructural y funcional muestran una afectación cortical mayor y más difusa, afectando al neocórtex (especialmente el precuneus). En conclusión, las evidencias actuales hacen pensar que la EAIP y la EAIT son variantes clínicas de una misma entidad, que en el caso de la EAIT se ve influida probablemente por factores asociados al envejecimiento.

Published
2024
Full Text
View/download PDF

25. Modulación de la actividad dopa-decarboxilasa central evaluada mediante PET con 18-F-dopa inducida por la administración crónica de levodopa en macacos con parkinsonismo inducido por MPTP

Author

Riverol, M. (Mario) and Luquin, M.R. (María Rosario)

Subjects
Levodopa, Marcadores dopaminérgicos presinápticos, Enfermedad de Parkinson, Modelos animales, 18F-Fluorodopa, Tomografía de emisión de positrones (PET)
Abstract

La enfermedad de Parkinson (EP) es una entidad frecuentre que afecta fundamentalmente a personas de edad avanzada. Los fármacos más utilizados para el control de los síntomas de esta entidad son la levodopa y los agonistas dopaminérgicos. Diversos estudios de tomografía de emisión de positrones (PET) con 18F-fluorodopa y DAT-scan realizados en pacientes tratados han mostrado, que tras 5 años dde tratamiento, la actividad dopa-descarboxilasa y del transportador de dopamina, fue mayor en los pacientes tratados con fármacos agonistas que en los tratados con levodopa. Estos hallazgos podrían indicar que los agonistas dopaminérgicos podrían evitar la pérdida de neuronas nigroestriatales. En contraposición, otros autores no consideran que estos hechos indiquen realmente un efecto neuroprotector, y se inclinan a pensar que se podría tratar de un efecto modulador enzimático inducido por el tratamiento. El objetivo de esta tesis es estudiar las modificaciones funcionales de la vía nigroestriada inducida por la administración crónica de levodopa a monos parkinsonianos. Se incluyeron once monos (Macaca fascicularis) en el estudio. Ocho de ellos recibieron inyecciones semanales de 1-metil-4-feni-1,2,3,6-tetrahidropiridina (MPTP) durante 7 semanas consecutivas para inducirles un parkinsonismo leve. Tras un mes de estabilización, cuatro de ellos fueron tratados con levodopa y otros cuatro con placebo (grupo placebo). El tratamiento con levodopa y placebo se administró durante 11 meses consecutivos. Además, se incluyeron tres animales control, intactos para el estudio histológico (grupo control). Se realizaron estudios de PET de 18F-Fluorodopa a los dos grupos de monos parkinsonianos según el siguiente esquema: 1. Basal, antes del tratamiento con MPTP; 2. Al mes de finalizar el tratamiento con MPTP y antes de iniciar la administración de levodopa; 3. Al día siguiente de terminar el tratamiento con levodopa; 4. Al mes de haber finalizado el tratamiento con levodopa; 5. A los 3 meses de haber finalizado el tratamiento con levodopa; 6. A los 6 meses de haber finalizado el tratamiento con levodopa. Tras la realización del último PET los animales fueron sacrificados y los cerrbros fijados para su posterior análisis histológico. Este análisis incluyó la cuantificación de neuronas tiroina hidroxilasa (TH) positivas en la sustancia negra, neuronas dopaminérgicas estriatales y de la expresión de las enzimas dopadescarboxiladsa (DDC), transportador de dopamina (DAT) y TH mediante Western blot. En el grupo de animales parkinsonianos tratados con levodopa se observó un incremento de la captación de 18F-Fluorodopa en el putamen anterior a los 3 y 6 meses de haber suspendido el tratamiento farmacológico, comparado con el grupo placebo. Ambos grupos de animales mostraron una reducción similar del número de neuronas dopaminérgicas en la sustancia negra, comparado con el grupo control. En cuanto al número de neuronas dopaminérgicas estriatales, se observó un aumento en los monos del grupo placebo con respecto al grupo control. En el grupo de animales tratados con levodopa, el número de estas células fue signigicativamente mayor que en el grupo placebo. Los niveles de DAT en el estriado se redujeron de igual manera en los dos grupos de monos parkinsonianos con respecto al grupo control. En los animales del grupo placebo se observó una disminución significativa del contenido de TH en todas las regiones del estriado con respecto al grupo control. En el grupo tratado con levodopa se observó una reducción significativa de TH en el putamen anterior y posterior. En este grupo de animales se objetivó una reducción mayor de los niveles de TH en el putamen posterior con respecto al grupo placebo. Los niveles de DDC fueron similares en los animales tratados con respecto al grupo control. Este estudio muestra que la administración crónica de levodopa a monos con una denervación parcial de la vía nigroestriada produce modificaciones en la actividad funcional de la misma.

Published
2013

26. Common folate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment

Author

Rajagopalan, P. (Priya), Jahanshad, N. (Neda), Stein, J.L. (Jason L.), Hua, X. (Xue), Madsen, S.K. (Sarah K.), Kohannim, O. (Omid), Hibar, D.P. (Derrek P.), Toga, A.W. (Arthur W.), Jack, C.R. (Clifford R. ), Saykin, A.J. (Andrew J.), Green, R.C. (Robert C.), Weiner, M.W. (Michael W.), Bis, J.C. (Joshua C.), Kuller, L.H. (Lewis H.), Riverol, M. (Mario), Becker, J.T. (James T.), Lopez, O.L. (Óscar L.), and Thompson, P.M. (Paul M.)

Subjects
Folate gene variant, MTHFR C677T, digestive system diseases
Abstract

A commonly carried C677T polymorphism in a folate-related gene, MTHFR, is associated with higher plasma homocysteine, a well-known mediator of neuronal damage and brain atrophy. As homocysteine promotes brain atrophy, we set out to discover whether people carrying the C677T MTHFR polymorphism which increases homocysteine, might also show systematic differences in brain structure. Using tensor-based morphometry, we tested this association in 359 elderly Caucasian subjects with mild cognitive impairment (MCI) (mean age: 75 ± 7.1 years) scanned with brain MRI and genotyped as part of Alzheimer's Disease Neuroimaging Initiative. We carried out a replication study in an independent, non-overlapping sample of 51 elderly Caucasian subjects with MCI (mean age: 76 ± 5.5 years), scanned with brain MRI and genotyped for MTHFR, as part of the Cardiovascular Health Study. At each voxel in the brain, we tested to see where regional volume differences were associated with carrying one or more MTHFR 'T' alleles. In ADNI subjects, carriers of the MTHFR risk allele had detectable brain volume deficits, in the white matter, of up to 2-8% per risk T allele locally at baseline and showed accelerated brain atrophy of 0.5-1.5% per T allele at 1 year follow-up, after adjusting for age and sex. We replicated these brain volume deficits of up to 5-12% per MTHFR T allele in the independent cohort of CHS subjects. As expected, the associations weakened after controlling for homocysteine levels, which the risk gene affects. The MTHFR risk variant may thus promote brain atrophy by elevating homocysteine levels. This study aims to investigate the spatially detailed effects of this MTHFR polymorphism on brain structure in 3D, pointing to a causal pathway that may promote homocysteine-mediated brain atrophy in elderly people with MCI.

Published
2012

27. Common folate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment

Author

Rajagopalan, P. (Priya), Jahanshad, N. (Neda), Stein, J.L. (Jason L.), Hua, X. (Xue), Madsen, S.K. (Sarah K.), Kohannim, O. (Omid), Hibar, D.P. (Derrek P.), Toga, A.W. (Arthur W.), Jack, C.R. (Clifford R. ), Saykin, A.J. (Andrew J.), Green, R.C. (Robert C.), Weiner, M.W. (Michael W.), Bis, J.C. (Joshua C.), Kuller, L.H. (Lewis H.), Riverol, M. (Mario), Becker, J.T. (James T.), Lopez, O.L. (Óscar L.), Thompson, P.M. (Paul M.), Rajagopalan, P. (Priya), Jahanshad, N. (Neda), Stein, J.L. (Jason L.), Hua, X. (Xue), Madsen, S.K. (Sarah K.), Kohannim, O. (Omid), Hibar, D.P. (Derrek P.), Toga, A.W. (Arthur W.), Jack, C.R. (Clifford R. ), Saykin, A.J. (Andrew J.), Green, R.C. (Robert C.), Weiner, M.W. (Michael W.), Bis, J.C. (Joshua C.), Kuller, L.H. (Lewis H.), Riverol, M. (Mario), Becker, J.T. (James T.), Lopez, O.L. (Óscar L.), and Thompson, P.M. (Paul M.)

Abstract

A commonly carried C677T polymorphism in a folate-related gene, MTHFR, is associated with higher plasma homocysteine, a well-known mediator of neuronal damage and brain atrophy. As homocysteine promotes brain atrophy, we set out to discover whether people carrying the C677T MTHFR polymorphism which increases homocysteine, might also show systematic differences in brain structure. Using tensor-based morphometry, we tested this association in 359 elderly Caucasian subjects with mild cognitive impairment (MCI) (mean age: 75 ± 7.1 years) scanned with brain MRI and genotyped as part of Alzheimer's Disease Neuroimaging Initiative. We carried out a replication study in an independent, non-overlapping sample of 51 elderly Caucasian subjects with MCI (mean age: 76 ± 5.5 years), scanned with brain MRI and genotyped for MTHFR, as part of the Cardiovascular Health Study. At each voxel in the brain, we tested to see where regional volume differences were associated with carrying one or more MTHFR 'T' alleles. In ADNI subjects, carriers of the MTHFR risk allele had detectable brain volume deficits, in the white matter, of up to 2-8% per risk T allele locally at baseline and showed accelerated brain atrophy of 0.5-1.5% per T allele at 1 year follow-up, after adjusting for age and sex. We replicated these brain volume deficits of up to 5-12% per MTHFR T allele in the independent cohort of CHS subjects. As expected, the associations weakened after controlling for homocysteine levels, which the risk gene affects. The MTHFR risk variant may thus promote brain atrophy by elevating homocysteine levels. This study aims to investigate the spatially detailed effects of this MTHFR polymorphism on brain structure in 3D, pointing to a causal pathway that may promote homocysteine-mediated brain atrophy in elderly people with MCI.

Published
2014

28. New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification

Author

Collantes, M. (María), Prieto-Azcárate, E. (Elena), Peñuelas-Sanchez, I. (Ivan), Blesa, J. (Javier), Juri, C. (Carlos), Marti-Climent, J.M. (Josep María), Quincoces, G. (Gemma), Arbizu, J. (Javier), Riverol, M. (Mario), Zubieta, J.L. (José L.), Rodriguez-Oroz, M.C. (María Cruz), Luquin, M.R. (María Rosario), Richter, J.A. (José Ángel), and Obeso, J.A. (José A.)

Subjects
PET, Macaca fascicularis neuroimaging, New MRIfor, 18F-DOPA, 11C-(+)-α-dihydrotetrabenazine templates, Advantages to improve quantification
Abstract

Normalization of neuroimaging studies to a stereotaxic space allows the utilization of standard volumes of interest (VOIs) and voxel-based analysis (SPM). Such spatial normalization of PET and MRI studies requires a high quality template image. The aim of this study was to create new MRI and PET templates of 18F-DOPA and 11C-(+)-α-dihydrotetrabenazine (11C-DTBZ) of the Macaca fascicularis brain, an important animal model of Parkinson's disease. MRI template was constructed as a smoothed average of the scans of 15 healthy animals, previously transformed into the space of one representative MRI. In order to create the PET templates, 18F-DOPA and 11C-DTBZ PET of the same subjects were acquired in a dedicated small animal PET scanner and transformed to the created MRI template space. To validate these templates for PET quantification, parametric values obtained with a standard VOI-map applied after spatial normalization to each template were statistically compared to results computed using individual VOIs drawn for each animal. The high correlation between both procedures validated the utilization of all the templates, improving the reproducibility of PET analysis. To prove the utility of the templates for voxel-based quantification, dopamine striatal depletion in a representative monkey treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was assessed by SPM analysis of 11C-DTBZ PET. A symmetric reduction in striatal 11C-DTBZ uptake was detected in accordance with the induced lesion. In conclusion, templates of M. fascicularis brain have been constructed and validated for reproducible and automated PET quantification. All templates are electronically available via the internet.

Published
2009

31. Determinación reciente de la colesterolemia en población adulta sana de Pamplona

Author

Martinez-Gonzalez, M.A. (Miguel Ángel), Hernandez-Perez, I. (I.), Villar, J. (J.), Riverol, M. (Mario), Miranda-Lloret, P. (P.), and Irala, J. (Jokin) de

Subjects
Ciencias de la Salud::Medicina preventiva [Materias Investigacion], Ciencias de la Salud::Endocrinología [Materias Investigacion]
Abstract

RESUMEN: Objetivo: Los objetivos del estudio fueron estimar la proporción de la población adulta sana de Pamplona que había determinado recientemente su colesterolemia e identificar los factores asociados a esta determinación. Métodos: Estudio transversal con entrevista personal a 1066 habitantes de Pamplona seleccionados por muestreo de rutas aleatorias. Se estratificó la ciudad en tres áreas urbanas según el nivel socioeconómico (alto, medio, bajo). La participación fue de un 91,8%. Utilizando como variable dependiente la determinación del colesterol total en los últimos 5 años, y como variables independientes la edad, el sexo, el nivel socioeconómico y el hábito tabáquico, se calcularon las odds ratios (OR) univariantes y se ajustó un modelo de regresión logística. Resultados: El 71,2% de la muestra estudiada (IC 95%: 68,3-74,O) se había determinado el colesterol en los últimos cinco años. Los no fumadores conocían más su colesterolemia que los fumadores con una OR ajustada de 1,38 (IC 95%: 1 ,O-1,9); los hombres lo conocían más que las mujeres (OR ajustada de 1,5; IC 95% 1,l-2,O). El conocimiento era menos frecuente en el grupo de edad 30 años. La determinación de la colesterolemia se daba más en los individuos de nivel socioeconómico medio y alto (OR ajustadas 3,2; IC 95% 2,2-4,7 y 1,6; IC 95% 1,l-2,3), respectivamente. Conclusiones: La determinación reciente del colesterol era más frecuente en individuos de mayor edad y en varones. La determinación de la colesterolemia era menos frecuente en algunos grupos con peor perfil de riesgo coronario (menor nivel socioeconómico y fumadores). Estos resultados sugieren la necesidad de intervenciones para mejorar el conocimientoy control de la colesterolemia en adultos sanos.

Published
2000

44. SPG11compound mutations in spastic paraparesis with thin corpus callosum

Author

Samaranch, L, Riverol, M, Masdeu, J C., Lorenzo, E, Vidal-Taboada, J M., Irigoyen, J, Pastor, M A., de Castro, P, and Pastor, P

Abstract

Autosomal recessive hereditary spastic paraparesis with thin corpus callosum (ARHSP-TCC) is being increasingly recognized as a variety of spastic paraplegia with mental retardation. SPG11gene mutations have been reported to be associated with ARHSP-TCC.

Published
2008
Full Text
View/download PDF

45. Efficacy and tolerability of a combination treatment of memantine and donepezil for alzheimer's disease: A literature review evidence

Author

Riverol, M., Andrea Slachevsky, and López, O. L.

Subjects
Article
Abstract

Two types of drugs have been approved for the symptomatic treatment of Alzheimer's disease (AD): the cholinesterase inhibitors (ChEIs) and memantine. There is a growing interest to know whether the combination of these drugs is safe and if it adds any clinical benefit to patients.To systematically review published medical literature assessing the efficacy and tolerability of a combination treatment of memantine and donepezil in AD patients.We searched PubMed for English and Spanish-language literature, using the terms "Alzheimer's disease," "cholinesterase inhibitors," "donepezil," and "memantine." Our review focused on clinical trials and observational studies.Eleven publications representing seven unique studies were selected for this review. Three were randomized double-blind, placebo-controlled trials and four were observational studies.Available data revealed that the combination of memantine and donepezil slowed down cognitive decline, prolonged functional independence, and improved behavioral symptoms in patients with moderate to severe AD. The long-term use of the dual therapy decreased the risk of nursing home admission. More longitudinal studies are needed to further examine the role of combined therapy in the management of AD patients.

46. Progressive supranuclear palsy: Common metabolic pattern in different variants

Author

Marti-Andres, G., Van Bommel, L., Meles, S., Riverol, M., Valenti, R., Kogan, R. V., Renken, R. J., Gurvits, V., Van Laar, T., Pagani, M., Prieto, E., Luquin, M. R., Leenders, K. L., Arbizu, J., Perceptual and Cognitive Neuroscience (PCN), Movement Disorder (MD), and Clinical Cognitive Neuropsychiatry Research Program (CCNP)

Catalog

Books, media, physical & digital resources
See catalog results